Psychopharmacology

, Volume 202, Issue 1–3, pp 385–396

Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat

  • Mark D. Black
  • Geoffrey B. Varty
  • Michal Arad
  • Segev Barak
  • Amaya De Levie
  • Denis Boulay
  • Philippe Pichat
  • Guy Griebel
  • Ina Weiner
Original Investigation

Abstract

Rationale

SSR103800 and SSR504734 are novel glycine transport 1 (GlyT1) inhibitors with therapeutic potential for the treatment of schizophrenia.

Objective

The present studies investigated the effects of GlyT1 inhibitors in acute pharmacological and neurodevelopmental models of schizophrenia using latent inhibition in the rat; these latent inhibition (LI) models are believed to be predictive for treatments of positive, negative, and cognitive aspects of schizophrenia.

Materials and methods

LI, the poorer conditioning to a previously irrelevant stimulus, was measured in a conditioned emotional response procedure in male rats. The effects of SSR103800 or SSR504734 (both at 1, 3, and 10 mg/kg, i.p.) were determined on amphetamine-induced disrupted LI, MK-801-induced abnormally persistent LI, and neurodevelopmentally induced abnormally persistent LI in adult animals that had been neonatally treated with a nitric oxide synthase inhibitor.

Results

SSR103800 (1 and 3 mg/kg) and SSR504734 (1 and 10 mg/kg) potentiated LI under conditions where LI was not present in nontreated controls and SSR103800 (1 mg/kg) reversed amphetamine-induced disrupted LI while not affecting LI on its own. Additionally, SSR103800 (1 and 3 mg/kg) and SSR504734 (3 and 10 mg/kg) reversed abnormally persistent LI induced by MK-801. In the neurodevelopmental model, SSR504734 (3 and 10 mg/kg) reverted the LI back to control (normal) levels.

Conclusions

These preclinical data, from acute and neurodevelopmental models, suggest that GlyT1 inhibition may exhibit activity in the positive, negative, and cognitive symptom domains of schizophrenia.

Keywords

Schizophrenia Cognition Glycine transport 1 inhibitors Latent inhibition Rat SSR504734 SSR103800 

References

  1. Aguado L, San Antonio A, Perez L, del Valle R, Gomez J (1994) Effects of the NMDA receptor antagonist ketamine on flavor memory: conditioned aversion, latent inhibition, and habituation of neophobia. Behav Neural Biol 61:271–281PubMedGoogle Scholar
  2. Akbarian S, Viñuela A, Kim JJ, Potkin SG, Bunney WE Jr, Jones EG (1993) Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 50(3):178–187PubMedGoogle Scholar
  3. Akbarian S, Kim JJ, Potkin SG, Hetrick WP, Bunney WE Jr, Jones EG (1996) Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch Gen Psychiatry 53(5):425–36PubMedGoogle Scholar
  4. Allen RM, Young SJ (1978) Phencyclidine-induced psychosis. Am J Psychiatry 135(9):1081–1084PubMedGoogle Scholar
  5. Atkinson BN, Bell SC, De Vivo M, Kowalski LR, Lechner SM, Ognyanov VI, Tham CS, Tsai C, Jia J, Ashton D, Klitenick MA (2001) ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol 60(6):1414–1420PubMedGoogle Scholar
  6. Bergeron R, Meyer TM, Coyle JT, Greene RW (1998) Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci 95(26):15730–15734PubMedGoogle Scholar
  7. Black MD, Selk DE, Hitchcock JM, Wettstein JG, Sorensen SM (1999) On the effect of neonatal nitric oxide synthase inhibition in rats: a potential neurodevelopmental model of schizophrenia. Neuropharmacology 38(9):1299–306PubMedGoogle Scholar
  8. Black MD, Simmonds J, Senyah Y, Wettstein JG (2002) Neonatal nitric oxide synthase inhibition: social interaction deficits in adulthood and reversal by antipsychotic drugs. Neuropharmacology 42(3):414–420PubMedGoogle Scholar
  9. Bloom FE (1993) Advancing neurodevelopmental origin for schizophrenia. Arch Gen Psychiatry 50:224–227PubMedGoogle Scholar
  10. Bogarts B (1993) Recent advances in the neuropathology of schizophrenia. Schizophr Bull 19:431–445Google Scholar
  11. Boulay D, Pichat P, Dargazanli G, Estenne-Bouhtou G, Terranova JP, Rogacki N, Stemmelin J, Coste A, Lanneau C, Desvignes C, Cohen C, Alonso R, Vigé X, Biton B, Steinberg R, Sevrin M, Oury-Donat F, George P, Bergis O, Griebel G, Avenet P, Scatton B (2008) Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol Biochem Behav (in press).Google Scholar
  12. Bouton ME (1993) Context, time, and memory retrieval in the interference paradigms of Pavlovian learning. Psychol Bull 114(1):80–99PubMedGoogle Scholar
  13. Brenman JE, Bredt DS (1997) Synaptic signaling by nitric oxide. Curr Opin Neurobiol 7(3):374–378PubMedGoogle Scholar
  14. Brown A, Carlyle I, Clark J, Hamilton W, Gibson S, McGarry G, McEachen S, Rae D, Thorn S, Walker G (2001) Discovery and SAR of org 24598—a selective glycine uptake inhibitor. Bioorg Med Chem Lett 11:2007–2009PubMedGoogle Scholar
  15. Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia—implications for schizophrenia and Parkinson’s disease. Trends Neurosci 13:272–276PubMedGoogle Scholar
  16. Carlsson A, Waters N, Waters S, Carlsson ML (2000) Network interactions in schizophrenia—therapeutic implications. Brain Res Brain Res Rev 31(2–3):342–349PubMedGoogle Scholar
  17. Carlsson ML, Carlsson A, Nilsson M (2004) Schizophrenia: from dopamine to glutamate and back. Curr Med Chem 11(3):267–277PubMedGoogle Scholar
  18. Coyle JT (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26(4–6):365–384PubMedGoogle Scholar
  19. Crider A (1997) Perseveration in schizophrenia. Schizophr Bull 23:63–74PubMedGoogle Scholar
  20. Cubelos B, Giménez C, Zafra F (2005) Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb Cortex 15(4):448–459PubMedGoogle Scholar
  21. Dawson TM, Bredt DS, Fotuhi M, Hwang PM, Snyder SH (1991) Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. Proc Nat Acad Sci 88(17):7797–7801PubMedGoogle Scholar
  22. Depoortere R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M, Heaulme M, Santucci V, Decobert M, Cudennec A, Voltz C, Boulay D, Terranova JP, Stemmelin J, Roger P, Marabout B, Sevrin M, Vige X, Biton B, Steinberg R, Francon D, Alonso R, Avenet P, Oury-Donat F, Perrault G, Griebel G, George P, Soubrie P, Scatton B (2005) Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30:1963–1985PubMedGoogle Scholar
  23. Enomoto T, Noda Y, Nabeshima T (2007) Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. Methods Find Exp Clin Pharmacol 29(4):291–301PubMedGoogle Scholar
  24. Evins AE, Amico E, Posever TA, Toker R, Goff DC (2002) D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 56(1–2):19–23PubMedGoogle Scholar
  25. Fejgin K, Pålsson E, Wass C, Svensson L, Klamer D (2008) Nitric oxide signaling in the medial prefrontal cortex is involved in the biochemical and behavioral effects of phencyclidine. Neuropsychopharmacology 33:1874–1883PubMedGoogle Scholar
  26. Gaisler-Salomon I, Weiner I (2003) Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology 166(4):333–342PubMedGoogle Scholar
  27. Gaisler-Salomon I, Diamant L, Rubin C, Weiner I (2008) Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered. Psychopharmacology 196(2):255–267PubMedGoogle Scholar
  28. Garthwaite J, Charles SL, Chess-Williams R (1988) Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 336(6197):385–388PubMedGoogle Scholar
  29. Gluck MR, Thomas RG, Davis KL, Haroutunian V (2002) Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am J Psychiatry 159(7):1165–1173PubMedGoogle Scholar
  30. Goff DC, Tsai G, Manoach DS, Coyle JT (1995) Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152(8):1213–1215PubMedGoogle Scholar
  31. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT (1996) D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 153(12):1628–1630PubMedGoogle Scholar
  32. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT (1999) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56(1):21–27PubMedGoogle Scholar
  33. Goldman-Rakic PS, Selemon LD (1997) Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 23(3):437–458PubMedGoogle Scholar
  34. Gomeza J, Ohno K, Betz H (2003) Glycine transporter isoforms in the mammalian central nervous system: structures, functions and therapeutic promises. Curr Opin Drug Discov Dev 6(5):675–682Google Scholar
  35. Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41(1):1–24PubMedGoogle Scholar
  36. Gray JA, Feldon J, Rawlins JNP, Hemsley DR, Smith AD (1991) The neuropsychology of schizophrenia. Behav Brain Sci 14:1–84Google Scholar
  37. Gray NS, Pickering AD, Hemsley DR, Dawling S, Gray JA (1992) Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology 107(2–3):425–430PubMedGoogle Scholar
  38. Gray JA, Joseph MH, Hemsley DR, Young AM, Warburton EC, Boulenguez P, Grigoryan GA, Peters SL, Rawlins JN, Taib CT, et al (1995) The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Behav Brain Res 71(1–2):19-31PubMedGoogle Scholar
  39. Harich S, Gross G, Bespalov A (2007) Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology 192(4):511–519PubMedGoogle Scholar
  40. Harsing LG Jr., Gacsalyi I, Szabo G, Schmidt E, Sziray N, Sebban C, Tesolin-Decros B, Matyus P, Egyed A, Spedding M, Levay G (2003) The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol Biochem Behav 74:811–825PubMedGoogle Scholar
  41. Heresco-Levy U (2003) Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27(7):1113–1123PubMedGoogle Scholar
  42. Heresco-Levy U, Javitt DC (2004) Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 66(2–3):89–96PubMedGoogle Scholar
  43. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M (2005) D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 57(6):577–585PubMedGoogle Scholar
  44. Hope BT, Michael GJ, Knigge KM, Vincent SR (1991) Neuronal NADPH diaphorase is a nitric oxide synthase. Proc Natl Acad Sci USA 88(7):2811–2814PubMedGoogle Scholar
  45. Hopper RA, Garthwaite J (2006) Tonic and phasic nitric oxide signals in hippocampal long-term potentiation. J Neurosci 26(45):11513–11521PubMedGoogle Scholar
  46. Ikemoto S, Panksepp J (1999) The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res Rev 31:6–41PubMedGoogle Scholar
  47. Jackson ME, Moghaddam B (2001) Amygdala regulation of nucleus accumbens dopamine output is governed by the prefrontal cortex. J Neurosci 21:676–681PubMedGoogle Scholar
  48. Javitt DC (2004) Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9(11):984–997, 979PubMedGoogle Scholar
  49. Javitt DC (2008) Glycine transport inhibitors and the treatment of schizophrenia. Biol Psychiatry 63(1):6–8PubMedGoogle Scholar
  50. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148(10):1301–1308PubMedGoogle Scholar
  51. Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, Lindenmayer JP, Suckow R, Zukin SR (2001) Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol 4(4):385–391PubMedGoogle Scholar
  52. Javitt DC, Hashim A, Sershen H (2005) Modulation of striatal dopamine release by glycine transport inhibitors. Neuropsychopharmacology 30(4):649–656PubMedGoogle Scholar
  53. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20(3):201–25PubMedGoogle Scholar
  54. Jentsch JD, Taylor JR (2001) Impaired inhibition of conditioned responses produced by subchronic administration of phencyclidine to rats. Neuropsychopharmacology 24:66–74PubMedGoogle Scholar
  55. Johnson JW, Ascher P (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325(6104):529–531PubMedGoogle Scholar
  56. Kapur S, Agid O, Mizrahi R, Li M (2006) How antipsychotics work—from receptors to reality. NeuroRx 3:10–21PubMedGoogle Scholar
  57. Kato K, Shishido T, Ono M, Shishido K, Kobayashi M, Niwa S (2001) Glycine reduces novelty- and methamphetamine-induced locomotor activity in neonatal ventral hippocampal damaged rats. Neuropsychopharmacology 24:330–332PubMedGoogle Scholar
  58. Kinney GG, Sur C, Burno M, Mallorga PJ, Williams JB, Figueroa DJ, Wittmann M, Lemaire W, Conn PJ (2003) The glycine transporter type 1 inhibitor N-[3-(4¢-fluorophenyl)-3-(4¢-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci 23:7586–7591PubMedGoogle Scholar
  59. Kiss JP, Vizi ES (2001) Nitric oxide: a novel link between synaptic and nonsynaptic transmission. Trends Neurosci 24(4):211–215PubMedGoogle Scholar
  60. Klamer D, Palsson E, Revesz A, Engel JA, Svensson L (2004) Habituation of acoustic startle is disrupted by psychotomimetic drugs: differential dependence on dopaminergic and nitric oxide modulatory mechanisms. Psychopharmacology (Berl) 176:440–450Google Scholar
  61. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3(8):711–715PubMedGoogle Scholar
  62. Kraepelin E (1919) Dementia Praecox and Paraphrenia. Livingstone, EdinburghGoogle Scholar
  63. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13(1):9–19PubMedGoogle Scholar
  64. Le Pen G, Kew J, Alberati D, Borroni E, Heitz MP, Moreau JL (2003) Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor. Biol Psychiatry 54:1162–1170PubMedGoogle Scholar
  65. Lipina T, Labrie V, Weiner I, Roder J (2005) Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology 179(1):54–67PubMedGoogle Scholar
  66. Lipton SA (2007) Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets 8(5):621–632PubMedGoogle Scholar
  67. Lipton SA, Choi YB, Takahashi H, Zhang D, Li W, Godzik A, Bankston LA (2002) Cysteine regulation of protein function—as exemplified by NMDA-receptor modulation. Trends Neurosci 25(9):474–480PubMedGoogle Scholar
  68. Lubow RE (1989) Latent inhibition and conditioned attention theory. Cambridge University Press, New YorkGoogle Scholar
  69. Lubow RE (2005) Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia. Schizophr Bull 31:139–153PubMedGoogle Scholar
  70. Lubow RE, Weiner I, Schnur P (1981) Conditioned attention theory. In: Bower GH (ed) The psychology of learning and motivation, vol 15. Academic, New York, pp 1–49Google Scholar
  71. Mackintosh NJ (1975) A theory of attention: variations in the associability of stimuli with reinforcement. Psychol Rev 82:276–298Google Scholar
  72. Martina M, Gorfinkel Y, Halman S, Lowe JA, Periyalwar P, Schmidt CJ, Bergeron R (2004) Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J Physiol 557:489–500PubMedGoogle Scholar
  73. Moghaddam B, Jackson ME (2003) Glutamatergic animal models of schizophrenia. Ann NY Acad Sci 1003:131–137PubMedGoogle Scholar
  74. Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921–2927PubMedGoogle Scholar
  75. Morice R (1990) Cognitive inflexibility and pre-frontal dysfunction in schizophrenia and mania. Br J Psychiatry 157:50–54PubMedGoogle Scholar
  76. Moser PC, Hitchcock JM, Lister S, Moran PM (2000) The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Rev 332–3:275–307Google Scholar
  77. Mouri A, Noda Y, Enomoto T, Nabeshima T (2007) Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int 51(2–4):173–184PubMedGoogle Scholar
  78. Palsson E, Klamer D, Wass C, Archer T, Engel JA, Svensson L (2005) The effects of phencyclidine on latent inhibition in taste aversion conditioning: differential effects of preexposure and conditioning. Behav Brain Res 157:139–146PubMedGoogle Scholar
  79. Rascle C, Mazas O, Vaiva G, Tournant M, Raybois O, Goudemand M, Thomas P (2001) Clinical features of latent inhibition in schizophrenia. Schizophr Res 51(2–3):149–61PubMedGoogle Scholar
  80. Robinson GB, Port RL, Stillwell EG (1993) Latent inhibition of the classically conditioned rabbit nictitating membrane response is unaffected by the NMDA antagonist MK-801. Psychobiology 21:120–124Google Scholar
  81. Roskams AJ, Bredt DS, Dawson TM, Ronnet GV (1994) Nitric oxide mediates the formation of synaptic connections in developing and regenerating olfactory receptor neurons. Neuron 13:289–299PubMedGoogle Scholar
  82. Sánchez-Islas E, León-Olea M (2004) Nitric oxide synthase inhibition during synaptic maturation decreases synapsin I immunoreactivity in rat brain. Nitric Oxide 10(3):141–149PubMedGoogle Scholar
  83. Stone JM, Morrison PD, Pilowsky LS (2007) Glutamate and dopamine dysregulation in schizophrenia—a synthesis and selective review. J Psychopharmacol 21(4):440–452PubMedGoogle Scholar
  84. Svensson TH (2000) Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res Brain Res Rev 31:320–329PubMedGoogle Scholar
  85. Swerdlow NR, Koob GF (1987) Dopamine, schizophrenia, mania, and depression: toward a unified hypothesis of cortico–striato–pallido–thalamic function. Behav Brain Sci 10:197–245CrossRefGoogle Scholar
  86. Tamminga CA, Holcomb HH, Gao XM, Lahti AC (1995) Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int Clin Psychopharmacology 10(Suppl 3):29–37Google Scholar
  87. Thornton JC, Dawe S, Lee C, Capstick C, Corr PJ, Cotter P, Frangou S, Gray NS, Russell MA, Gray JA (1996) Effects of nicotine and amphetamine on latent inhibition in human subjects. Psychopharmacology 127(2):164–173PubMedGoogle Scholar
  88. Tsai G, Yang P, Chung LC, Lange N, Coyle JT (1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44(11):1081–1089PubMedGoogle Scholar
  89. Turgeon SM, Auerbach EA, Heller MA (1998) The delayed effects of phencyclidine (PCP) disrupt latent inhibition in a conditioned taste aversion paradigm. Pharmacol Biochem Behav 60:553–558PubMedGoogle Scholar
  90. Turgeon SM, Auerbach EA, Duncan-Smith MK, George JR, Graves WW (2000) The delayed effects of DTG and MK-801 on latent inhibition in a conditioned taste-aversion paradigm. Pharmacol Biochem Behav 66(3):533–539PubMedGoogle Scholar
  91. van der Meulen JA, Bilbija L, Joosten RN, de Bruin JP, Feenstra MG (2003) The NMDA-receptor antagonist MK-801 selectively disrupts reversal learning in rats. Neuroreport 14:2225–2228PubMedGoogle Scholar
  92. Wass C, Archer T, Pålsson E, Fejgin K, Alexandersson A, Klamer D, Engel JA, Svensson L (2006) Phencyclidine affects memory in a nitric oxide-dependent manner: working and reference memory. Behav Brain Res 174(1):49–55PubMedGoogle Scholar
  93. Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44(7):660–669PubMedGoogle Scholar
  94. Weinberger DR, Lipska BK (1995) Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr Res 16:87–110PubMedGoogle Scholar
  95. Weiner I (1990) Neural substrates of latent inhibition: the switching model. Psychol Bull 108(3):442–461PubMedGoogle Scholar
  96. Weiner I (2003) The “two-headed” latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology 169(3–4):257–297PubMedGoogle Scholar
  97. Weiner I, Feldon J (1986) Reversal and nonreversal shifts under amphetamine. Psychopharmacology 89(3):355–359PubMedGoogle Scholar
  98. Weiner I, Feldon J (1992) Phencyclidine does not disrupt latent inhibition in rats: implications for animal models of schizophrenia. Pharmacol Biochem Behav 42(4):625–631PubMedGoogle Scholar
  99. Weiner I, Feldon J (1997) The switching model of latent inhibition: an update of neural substrates. Behav Brain Res 88(1):11–25PubMedGoogle Scholar
  100. Weiner I, Joel D (2002) Dopamine in schizophrenia: Dysfunctional information processing in basal ganglia-thalamocortical split circuits. In: Di Chiara G (ed) Handbook of experimental pharmacology: dopamine in the CNS. Springer, Berlin, pp 417–472Google Scholar
  101. Weiner I, Lubow RE, Feldon J (1984) Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology 83(2):194–199PubMedGoogle Scholar
  102. Weiner I, Gal G, Rawlins JN, Feldon J (1996) Differential involvement of the shell and core subterritories of the nucleus accumbens in latent inhibition and amphetamine-induced activity. Behav Brain Res 81(1–2):123–133PubMedGoogle Scholar
  103. Wu W, Li L, Yick LW, Chai H, Yang Y, Prevette DM, Oppenheim RW (2003) GDNF and BDNF alter the expression of neuronal NOS, c-Jun, and p75 and prevent motoneurons death following spinal root avulsion in adult rats. J Neurotrauma 20:603–612PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Mark D. Black
    • 1
  • Geoffrey B. Varty
    • 1
  • Michal Arad
    • 3
  • Segev Barak
    • 3
  • Amaya De Levie
    • 3
  • Denis Boulay
    • 2
  • Philippe Pichat
    • 2
  • Guy Griebel
    • 2
  • Ina Weiner
    • 3
  1. 1.CNS DepartmentSanofi-AventisBridgewaterUSA
  2. 2.CNS DepartmentSanofi-AventisBagneuxFrance
  3. 3.Department of PsychologyTel Aviv UniversityTel AvivIsrael

Personalised recommendations